Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory

 

 

 
Pfizer Reports on Hemophilia Studies at WFH Congress
 

Pfizer Inc. presented the results of preclinical hemophilia treatment-related studies at the World Federation of Hemophilia (WFH) 2010 Congress in Buenos Aires, Argentina, in July.

 

Pfizer reported that preclinical studies in mice suggest that there is a potential use for recombinant factor Xa to ensure adequate clotting in hemophilia patients, bypassing existing deficiencies in other factors, such as factor VIII or IX. Other preclinical studies showed that an enhanced recombinant factor VIIa molecule might effectively treat bleeding while decreasing inhibitor rates.

 

“We are very excited to present these data, which highlights the strength of our pipeline and our enduring commitment to provide recombinant products for the hemophilia community,” said Brenda Cooperstone, MD, vice president of clinical development and medical affairs for the Specialty Care Business Unit at Pfizer. “Our investigation of novel therapies for hemophilia treatment remains ongoing and we will continue to work closely with our partners—including the World Federation of Hemophilia—to help improve hemophilia care worldwide.”

 

Source: EurekAlert, July 9, 2010